Latest Breaking News On - ஜாக்லின் ஜாஃப் - Page 1 : comparemela.com
Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Mustang Bio Awarded Massachusetts Life Sciences Center Tax
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
Fortress Biotech, Inc.May 16, 2021 GMT
Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021
On track to report top-line results from the registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma by year-end 2021
Ended first quarter 2021 with $291.5 million in consolidated cash, cash equivalents and restricted cash
NEW YORK, May 16, 2021 (GLOBE NEWSWIRE) Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced financial results and recent corporate highlights for the first quarter ended March 31,
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad .
Fortress Biotech, Inc.May 10, 2021 GMT
Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic kidney disease and heart failure
Dotinurad (URECE® tablet) was approved in Japan in 2020 as a once-daily oral therapy for gout and hyperuricemia
Dotinurad was efficacious and well-tolerated in more than 500 Japanese patients treated for up to 58 weeks in Phase 3 clinical trials
NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company, today announced that it has entered into an exclusive licensing agreement with Fuji Yakuhin Co. Ltd. (“Fuji”) to develop Dot